文献速递妇科

促性腺激素释放激素拮抗剂联合疗法用于围绝经期子宫肌瘤管理

Gonadotropin-Releasing Hormone Antagonist Combination Therapies for Perimenopausal Uterine Leiomyoma Care.
PubMed 文献 · Obstet Gynecol · 2026-08-13

本文为临床视角综述,基于机制比较、随机试验数据与长期安全性证据,评估GnRH拮抗剂联合疗法在围绝经期子宫肌瘤管理中的作用。该疗法可快速、可逆地抑制促性腺激素分泌且不引起雌激素 flare,持续减少肌瘤相关月经过多、改善压迫症状及贫血,被视为针对围绝经期有症状肌瘤患者的一种限时、耐受性良好的靶向治疗选择。

要点

  • GnRH拮抗剂联合疗法快速、可逆抑制促性腺激素分泌,不引起雌激素 flare。
  • 可持续减少肌瘤相关月经过多,管理压迫症状并改善贫血。
  • 适用于围绝经期有症状子宫肌瘤患者,为限时、耐受性良好的靶向选择。

核心结论

  • GnRH拮抗剂联合疗法是一种针对围绝经期有症状子宫肌瘤的靶向、限时且耐受性良好的治疗选择,填补了该人群的关键治疗缺口。

研究设计与样本

  • 临床视角综述,基于机制比较、随机试验数据与长期安全性发现进行证据汇总。

主要发现

  • GnRH拮抗剂联合疗法可快速、可逆地抑制促性腺激素分泌,且不引起雌激素 flare。
  • 该疗法持续减少肌瘤相关月经过多,管理压迫相关症状并改善贫血。
  • 文章还指出了围绝经期传统激素管理与期待管理的局限性。

临床怎么用

  • 围绝经期有症状子宫肌瘤患者可考虑GnRH拮抗剂联合疗法作为限时靶向治疗。
  • 临床需关注患者选择与监测的实际考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this clinical perspective, we examine the role of gonadotropin-releasing hormone (GnRH) antagonist combination therapies in the management of uterine leiomyomas during perimenopause, a period marked by hormonal variability and heightened symptom burden. Drawing on mechanistic comparisons, randomized trial data, and long-term safety findings, we review evidence demonstrating that GnRH antagonist combination therapies provide rapid, reversible suppression of gonadotropin secretion without an estrogen flare. This, in turn, results in consistent reductions in heavy menstrual bleeding associated with leiomyomas, management of bulk-related symptoms, and improvement with anemia. We further highlight limitations of conventional hormonal and expectant management strategies during perimenopause and discuss practical considerations for patient selection and monitoring. Collectively, these findings support GnRH antagonist combination therapy as a targeted, time-limited, and well-tolerated treatment option that addresses a critical therapeutic gap for perimenopausal patients with symptomatic uterine leiomyomas.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Yap JQ, Laughlin-Tommaso SK. Gonadotropin-Releasing Hormone Antagonist Combination Therapies for Perimenopausal Uterine Leiomyoma Care. Obstet Gynecol. 2026. PMID: 42594381. doi:10.1097/AOG.0000000000006399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。